Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are comparing the effects of two treatment combinations in adults with stage IV or recurrent non-squamous non-small cell lung cancer NSCLC that has a PD-L1 expression of 1% or higher. This phase 3 trial investigates whether Nivolumab and Relatlimab combined with chemotherapy works differently than Pembrolizumab with chemotherapy as first-line treatment for this condition. The study is sponsored by Bristol-Myers Squibb and uses a randomized parallel design. Participants will be assigned to one of two groups one group receives Nivolumab and Relatlimab with chemotherapy drugs, while the other group receives Pembrolizumab with chemotherapy. Chemotherapy may include drugs such as Carboplatin, Pemetrexed, or Cisplatin, given at specified doses on specific days. Treatment schedules and doses are carefully planned, and participants are treated during the trial period. During the study, participants undergo regular assessments to measure overall survival, progression-free survival, response rates, and duration of response, with follow-up lasting up to five years. Researchers also track adverse events and immune-related side effects for up to 2.5 years. Quality of life is monitored through symptom questionnaires. Assessments include imaging scans and laboratory tests to evaluate disease status and treatment effects. The total duration of participation may extend over several years to capture long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating the efficacy and safety of adagrasib MRTX849 alone and combined with pembrolizumab in patients with advanced or metastatic non-small cell lung cancer NSCLC who have a KRAS G12C mutation. The study includes both Phase 2 and Phase 3 portions, focusing on patients eligible for first-line treatment with varying levels of PD-L1 expression. The trial compares adagrasib combined with pembrolizumab to pembrolizumab alone in patients with high PD-L1 expression. In Phase 2, patients are divided into three groups based on PD-L1 TPS scores two groups with scores below 1% receive either adagrasib monotherapy or adagrasib plus pembrolizumab, and one group with scores of 1% or higher receives the combination. Phase 3 randomizes patients with PD-L1 TPS of 50% or higher to receive either adagrasib plus pembrolizumab or pembrolizumab alone. Adagrasib is taken orally twice daily, while pembrolizumab is given intravenously every three weeks. Participants undergo regular assessments including brain imaging, tumor measurements, and quality of life questionnaires. Researchers monitor treatment effects, safety, drug levels in blood, and lung cancer symptoms over periods of up to 22 months in Phase 2 and 36 months in Phase 3. The study also evaluates progression-free survival, response duration, and other outcomes to understand the treatments impact.
Actively Recruiting
Researchers are evaluating Izalontamab Brengitecan BMS-986507 compared with platinum-based chemotherapy combined with pemetrexed for patients with EGFR-mutated non-small cell lung cancer that has progressed despite prior EGFR tyrosine kinase inhibitor TKI therapy. This study is a randomized, open-label phase 23 trial sponsored by Bristol-Myers Squibb, aiming to determine effective treatment options after failure of EGFR TKI therapy. Participants receive one of several regimens including Izalontamab Brengitecan or platinum-based chemotherapy with pemetrexed, using drugs such as carboplatin, cisplatin, and pemetrexed administered at specified doses on specified days. The study uses a parallel design with randomized assignment to different treatment arms to compare outcomes. Throughout the study, participants will be monitored for progression-free survival and response to treatment using RECIST v1.1 criteria through blinded independent central review, with assessments continuing for up to three years. The recommended phase 3 dose of Izalontamab Brengitecan will be determined about three months after the first dose. Overall survival and multiple secondary outcomes will also be tracked, with the study lasting until November 2030.
Actively Recruiting
Researchers are studying treatments for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors overexpress HER2 and have PD-L1 TPS less than 50%. This trial compares the combination of trastuzumab deruxtecan T-DXd with pembrolizumab against platinum-based chemotherapy combined with pembrolizumab. Participants have not received prior therapy for their advanced or metastatic NSCLC and lack known actionable genomic alterations with available targeted treatments. The study involves two treatment groups. One group receives T-DXd at 5.4 mgkg intravenously every three weeks alongside pembrolizumab at 200 mg IV every three weeks. The other group receives pemetrexed at 500 mgm IV every three weeks plus a platinum chemotherapy agent cisplatin or carboplatin combined with pembrolizumab at 200 mg IV every three weeks. Treatment continues as per protocol for first-line therapy in this population. Participants will be monitored regularly for disease progression and survival outcomes, with progression-free survival assessed by independent central review up to approximately 54 months and overall survival up to about 85 months. Tumor tissue samples will be assessed for HER2 and PD-L1 expression. Safety and treatment effects will be evaluated throughout the study, which may last several years until study completion in 2032.